Synergistic cytotoxicity of gemcitabine, clofarabine and edelfosine in lymphoma cell lines

por Valdez, B C, Zander, A R, Song, G, Murray, D, Nieto, Y, Li, Y, Champlin, R E, Andersson, B S
Publicado 2014

Romidepsin targets multiple survival signaling pathways in malignant T cells

por Valdez, B C, Brammer, J E, Li, Y, Murray, D, Liu, Y, Hosing, C, Nieto, Y, Champlin, R E, Andersson, B S
Publicado 2015

Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies

por Lekakis, L, Giralt, S, Couriel, D, Shpall, E J, Hosing, C, Khouri, I F, Anderlini, P, Korbling, M, Martin, T, Champlin, R E, de Lima, M
Publicado 2006

Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial

por Shah, J J, Feng, L, Thomas, S K, Berkova, Z, Weber, D M, Wang, M, Qazilbash, M H, Champlin, R E, Mendoza, T R, Cleeland, C, Orlowski, R Z
Publicado 2016

P1344: METHODOLOGY OF AN INTERNATIONAL MULTI-CENTER RETROSPECTIVE REVIEW OF TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (TA-TMA) BY THE TA-TMA WORKING GROUP

por Ho, V., Duarte, R. F., Boelens, J.-J., Cairo, M. S., Champlin, R. E., Giralt, S., Hamadani, M., Higham, C. S., Jerkins, J. H., Laurence, J., Mayer, S., Nakamura, R., Penack, O., Perales, M.-A., Rondón, G., Scordo, M., Hingorani, S., Vasu, S.
Publicado 2022